

**STATE OF HAWAII
DEPARTMENT OF HUMAN SERVICES
MED-QUEST DIVISION**

Report to the Hawaii State Legislature
on Psychotropic Medication
pursuant to section 346-59.9, Hawaii Revised Statutes

December 2016

Section 346-59.9, Hawaii Revised Statutes, requires the Department of Human Services to report annually on:

- (1) The number of brand-name and generic prescriptions written to which this section applies; and
- (2) The amount expended on brand-name prescriptions and the amount expended on generic prescriptions written each fiscal year to which this section applies.

The information is provided in the tables below.

Hawaii Medicaid Psychotropic Cost for Fiscal Year 2016

Includes QUEST Integration (QI) Health Plans, Community Care Services (CCS) and Fee-For-Service (FFS)

	Total Number of Claims				Total Expenditure			
	Brand		Generic		Brand		Generic	
	#	%	#	%	\$	%	\$	%
Antipsychotic Subtotal*								
7/1/2015-6/30/2016	8,212	16%	43,549	84%	\$9,867,225	41%	\$9,480,161	49%
Antidepressant Total								
7/1/2015-6/30/2016	5,093	4%	132,984	96%	\$1,457,277	33%	\$2,927,020	67%
Anti-anxiety Total								
7/1/2015-6/30/2016	427	1%	69,597	99%	\$216,186	28%	\$568,327	72%

*This is a subtotal of five QI health plans (out of six) plus FFS and CCS, due to data pending verification from one QI health plan and an initial analysis.

The subtotal¹ cost for psychotropic medication in SFY 2016 is approximately \$24,500,000. This subtotal includes the QI health plans (\$14,300,000) and the CSS (\$10,200,000) program. The FFS program is minor in total costs (\$21,500).

¹ This is a subtotal of five QI health plans (out of six), due to data pending verification from one QI health plan for the antipsychotic medications, plus the totals of the antidepressant and anti-anxiety medications for all six QI health plans, FFS and CCS. This is an initial analysis.

Hawaii Medicaid Psychotropic Cost: Quest Integration and Fee-For-Service

For comparison, CCS is not included.

		Total Number of Claims				Total Expenditures			
		Brand		Generic		Brand		Generic	
		#	%	#	%	\$	%	\$	%
Antipsychotic									
	7/1/2009-6/30/2010	41,568	77%	12,279	23%	\$20,120,498	93%	\$1,462,845	7%
	7/1/2010-6/30/2011	44,771	76%	13,863	24%	\$25,292,347	95%	\$1,399,257	5%
	7/1/2011-6/30/2012	36,942	60%	24,660	40%	\$23,577,237	81%	\$5,392,685	19%
	7/1/2012-6/30/2013	24,124	38%	38,545	62%	\$18,854,977	78%	\$5,343,676	22%
	7/1/2013-6/30/2014	17,543	38%	29,109	62%	\$15,400,608	81%	\$3,501,443	19%
	7/1/2014-6/30/2015	18,058	36%	32,484	64%	\$15,816,746	76%	\$5,054,661	24%
	7/1/2015-6/30/2016*	5,159	18%	23,837	82%	\$5,828,675	59%	\$4,038,571	41%
Antidepressant									
	7/1/2009-6/30/2010	22,358	25%	66,509	75%	\$3,403,691	60%	\$2,290,816	40%
	7/1/2010-6/30/2011	18,796	19%	80,114	81%	\$2,900,028	51%	\$2,838,201	49%
	7/1/2011-6/30/2012	13,520	13%	92,124	87%	\$2,487,651	50%	\$2,528,206	50%
	7/1/2012-6/30/2013	9,521	9%	102,226	91%	\$2,274,479	47%	\$2,578,048	53%
	7/1/2013-6/30/2014	5,017	5%	98,423	95%	\$1,428,173	36%	\$2,514,924	64%
	7/1/2014-6/30/2015	5,242	5%	96,203	95%	\$1,349,207	38%	\$2,217,943	62%
	7/1/2015-6/30/2016	4,786	4%	114,760	96%	\$1,375,577	37%	\$2,350,237	63%
Anti-anxiety									
	7/1/2009-6/30/2010	293	1%	52,690	99%	\$40,861	7%	\$585,858	93%
	7/1/2010-6/30/2011	206	<1%	56,699	100%	\$38,126	6%	\$615,984	94%
	7/1/2011-6/30/2012	153	<1%	59,655	100%	\$39,009	6%	\$622,672	94%
	7/1/2012-6/30/2013	114	<1%	54,721	100%	\$44,039	8%	\$503,706	92%
	7/1/2013-6/30/2014	120	<1%	52,292	100%	\$55,603	12%	\$424,190	88%
	7/1/2014-6/30/2015	84	<1%	53,634	100%	\$61,460	14%	\$377,300	86%
	7/1/2015-6/30/2016	415	1%	63,258	99%	\$215,465	30%	\$510,127	70%

*This is a subtotal of five QI plans (out of six) plus FFS, due to data pending verification from one plan, and an initial analysis.

Medicaid Fee-For-Service Psychotropic Cost

	Total Number of Claims				Total Expenditure				Total No. Unique Utilizers	
	Brand		Generic		Brand		Generic			
	#	%	#	%	\$	%	\$	%		
Antipsychotic										
7/1/09-6/30/10*	431	77%	121	23%	\$173,656	94%	\$11,761	4%	277	
7/1/10-6/30/11	243	68%	112	32%	\$108,078	91%	\$10,354	9%	201	
7/1/11-6/30/12	160	54%	134	46%	\$71,790	81%	\$16,384	19%	173	
7/1/12-6/30/13	10	24%	32	76%	\$7,623	76%	\$2,371	24%	20	
7/1/13-6/30/14	5	11%	40	89%	\$3,443	42%	\$4,797	58%	14	
7/1/14-6/30/15	4	11%	31	89%	\$3,323	46%	\$3,869	54%	10	
7/1/15-6/30/16	3	5%	62	95%	\$4,106	21%	\$15,938	79%	7	
Antidepressant										
7/1/09-6/30/10*	154	22%	561	78%	\$17,861	52%	\$16,566	48%	411	
7/1/10-6/30/11	77	15%	449	85%	\$11,535	40%	\$15,732	60%	324	
7/1/11-6/30/12	39	10%	368	90%	\$6,100	38%	\$9,790	66%	273	
7/1/12-6/30/13	0	0%	102	100%	\$0	0%	\$2,269	100%	49	
7/1/13-6/30/14	0	0%	90	100%	\$0	0%	\$1,766	100%	27	
7/1/14-6/30/15	0	0%	38	100%	\$0	0%	\$783	100%	10	
7/1/15-6/30/16	0	0%	54	100%	\$0	0%	\$1,134	100%	10	
Anti-anxiety										
7/1/09-6/30/10*	0	0%	360	100%	\$0	0%	\$2,969	100%	245	
7/1/10-6/30/11	0	0%	263	100%	\$0	0%	\$3,142	100%	202	
7/1/11-6/30/12	0	0%	237	100%	\$0	0%	\$3,092	100%	175	
7/1/12-6/30/13	0	0%	78	100%	\$0	0%	\$687	100%	52	
7/1/13-6/30/14	0	0%	72	100%	\$0	0%	\$578	100%	42	
7/1/14-6/30/15	0	0%	32	100%	\$0	0%	\$302	100%	25	
7/1/15-6/30/16	0	0%	51	100%	\$0	0%	\$319	100%	29	

*FFS Aged, Blind and Disabled moved into QUEST Expanded Access on February 1, 2009.

AlohaCare QUEST Integration Psychotropic Cost

	Total Number of Claims				Total Expenditure				Total No. Unique Utilizers
	Brand		Generic		Brand		Generic		
	#	%	#	%	\$	%	\$	%	
Antipsychotic									
7/1/09-6/30/10	5,887	85%	1,022	15%	\$2,182,797	94%	\$141,089	6%	1,259
7/1/10-6/30/11	6,545	81%	1,460	19%	\$2,915,457	94%	\$183,521	6%	1,410
7/1/11-6/30/12	5,062	64%	2,887	36%	\$2,614,657	83%	\$523,881	17%	1,392
7/1/12-6/30/13	3,517	46%	4,138	54%	\$1,951,363	80%	\$484,644	20%	1,220
7/1/13-6/30/14	2,703	40%	4,010	60%	\$2,323,691	86%	\$365,329	14%	1,088
7/1/14-6/30/15*	1,550	34%	3,021	66%	\$1,404,173	86%	\$224,212	14%	907
7/1/15-6/30/16	785	16%	4,059	84%	\$794,990	52%	\$743,892	48%	926
Antidepressant									
7/1/09-6/30/10	4,380	26%	12,376	74%	\$602,689	59%	\$423,742	41%	3,355
7/1/10-6/30/11	3,580	20%	14,613	80%	\$509,803	46%	\$607,128	54%	3,623
7/1/11-6/30/12	2,303	12%	16,663	88%	\$375,886	38%	\$621,367	62%	3,593
7/1/12-6/30/13	1,913	10%	17,247	90%	\$274,955	36%	\$489,987	64%	3,314
7/1/13-6/30/14	712	4%	17,915	96%	\$170,763	24%	\$553,019	76%	3,192
7/1/14-6/30/15*	259	2%	16,577	98%	\$61,252	17%	\$305,263	83%	2,968
7/1/15-6/30/16	291	2%	18,060	98%	\$78,660	20%	\$321,469	80%	3,262
Anti-anxiety									
7/1/09-6/30/10	15	<1%	8,206	100%	\$2,505	3%	\$79,318	97%	1,786
7/1/10-6/30/11	18	<1%	8,111	100%	\$1,951	2%	\$80,947	98%	1,894
7/1/11-6/30/12	2	<1%	8,362	100%	\$247	<1%	\$93,660	100%	1,835
7/1/12-6/30/13	0	0%	6,731	100%	\$0	0%	\$61,849	100%	1,734
7/1/13-6/30/14*	28	<1%	11,583	100%	\$8,176	6%	\$138,556	94%	2,290
7/1/14-6/30/15*	16	<1%	11,658	100%	\$5,809	4%	\$139,536	96%	3,058
7/1/15-6/30/16	54	<1%	12,269	100%	\$20,744	10%	\$182,755	90%	2,968

*Change from last year's reported data is due to health plan's correction of data.

HMSA QUEST Integration Psychotropic Cost

	Total Number of Claims				Total Expenditure				Total No. Unique Utilizers
	Brand		Generic		Brand		Generic		
	#	%	#	%	\$	%	\$	%	
Antipsychotic									
7/1/09-6/30/10	11,615	83%	2,430	17%	\$4,319,335	96%	\$160,146	4%	2,127*
7/1/10-6/30/11	11,406	80%	2,810	19%	\$4,847,964	98%	\$103,154	2%	2,171
7/1/11-6/30/12	9,978	66%	5,290	34%	\$5,009,526	88%	\$664,503	12%	2,221
7/1/12-6/30/13	7,586	44%	9,642	56%	\$4,626,576	86%	\$768,865	14%	2,469
7/1/13-6/30/14	7,055	45%	8,755	55%	\$5,011,583	90%	\$555,836	10%	2,429
7/1/14-6/30/15	6,074	41%	8,770	59%	\$4,866,243	89%	\$598,551	11%	2,214
7/1/15-6/30/16	3,423	20%	13,886	80%	\$3,004,756	60%	\$2,003,993	40%	2,434
Antidepressant									
7/1/09-6/30/10	8,864	27%	24,262	73%	\$1,185,654	58%	\$875,185	42%	5,565*
7/1/10-6/30/11	7,410	19%	30,843	81%	\$1,004,692	51%	\$947,123	49%	6,199
7/1/11-6/30/12	5,237	13%	35,348	87%	\$904,502	54%	\$781,470	46%	6,442
7/1/12-6/30/13	3,870	8%	43,422	92%	\$902,444	51%	\$880,628	49%	7,428
7/1/13-6/30/14	2,376	5%	46,341	95%	\$620,624	42%	\$871,708	58%	7,895
7/1/14-6/30/15	2,279	4%	50,516	96%	\$562,786	38%	\$909,438	62%	8,276
7/1/15-6/30/16	2,622	4%	57,011	96%	\$756,377	49%	\$783,261	51%	8,893
Anti-anxiety									
7/1/09-6/30/10	18	<1%	11,536	100%	\$5,910	4%	\$137,248	96%	2,360*
7/1/10-6/30/11	31	<1%	13,316	100%	\$6,803	6%	\$111,448	94%	2,667
7/1/11-6/30/12	18	<1%	13,545	100%	\$4,540	4%	\$116,889	96%	2,488
7/1/12-6/30/13	34	<1%	17,584	100%	\$10,378	8%	\$118,503	92%	3,606
7/1/13-6/30/14	44	<1%	21,076	100%	\$18,801	14%	\$115,739	86%	4,461
7/1/14-6/30/15	30	<1%	22,374	100%	\$37,788	29%	\$92,723	71%	4,979
7/1/15-6/30/16	24	<1%	24,761	100%	\$60,906	43%	\$81,824	57%	5,374

*The change of a pharmacy claims processor during this period results in some inconsistencies in data sets.

Kaiser QUEST Integration Psychotropic Cost

	Total Number of Claims				Total Expenditure				Total No. Unique Utilizers
	Brand		Generic		Brand		Generic		
	#	%	#	%	\$	%	\$	%	
Antipsychotic									
7/1/09-6/30/10	714	53%	628	47%	\$210,251	98%	\$3,932	2%	289
7/1/10-6/30/11	853	54%	730	46%	\$301,307	98%	\$6,176	2%	360
7/1/11-6/30/12	625	38%	1,023	62%	\$258,603	89%	\$32,444	11%	372
7/1/12-6/30/13	404	24%	1,307	76%	\$204,739	92%	\$17,232	8%	335
7/1/13-6/30/14	391	24%	1,251	76%	\$242,048	94%	\$16,517	6%	321
7/1/14-6/30/15	252	22%	905	78%	\$197,867	75%	\$65,471	25%	353
7/1/15-6/30/16	49	3%	1,379	97%	\$48,694	27%	\$134,555	73%	417
Antidepressant									
7/1/09-6/30/10	497	8%	5,857	92%	\$75,263	66%	\$38,422	34%	1,181
7/1/10-6/30/11	463	6%	6,968	94%	\$80,249	66%	\$41,292	34%	1,378
7/1/11-6/30/12	485	5%	8,444	95%	\$107,488	66%	\$55,350	34%	1,589
7/1/12-6/30/13	458	5%	7,943	95%	\$124,731	71%	\$51,058	29%	1,398
7/1/13-6/30/14	248	4%	6,811	96%	\$82,406	52%	\$77,015	49%	1,358
7/1/14-6/30/15	20	<1%	5,582	100%	\$8,669	14%	\$51,510	86%	1,524
7/1/15-6/30/16	37	<1%	6,143	100%	\$17,195	30%	\$39,477	70%	1,721
Anti-anxiety									
7/1/09-6/30/10	1	<1%	2,469	100%	\$147	3%	\$4,851	97%	648
7/1/10-6/30/11	1	<1%	2,789	100%	\$661	11%	\$5,101	89%	777
7/1/11-6/30/12	15	<1%	2,972	100%	\$5,503	53%	\$4,915	47%	867
7/1/12-6/30/13	13	<1%	2,646	100%	\$4,555	53%	\$4,095	47%	758
7/1/13-6/30/14	13	<1%	2,374	100%	\$6,912	65%	\$3,746	35%	760
7/1/14-6/30/15	2	<1%	2,758	100%	\$50	1%	\$3,843	99%	898
7/1/15-6/30/16	1	<1%	3,403	100%	\$48	<1%	\$11,032	100%	1,041

Ohana Health Quest Integration Psychotropic Cost

	Total Number of Claims				Total Expenditure				Total No. Unique Utilizers	
	Brand		Generic		Brand		Generic			
	#	%	#	%	\$	%	\$	%		
Antipsychotic										
7/1/09-6/30/10	15,653	76%	5,068	24%	\$7,510,115	92%	\$645,522	8%	1,944	
7/1/10-6/30/11	18,771	76%	6,008	24%	\$10,069,923	93%	\$701,013	7%	2,164	
7/1/11-6/30/12	15,357	58%	11,280	42%	\$9,537,668	75%	\$3,122,545	25%	2,129	
7/1/12-6/30/13	9,555	35%	17,735	65%	\$7,532,671	66%	\$3,936,457	34%	2,216	
7/1/13-6/30/14*	Data Discrepancies Under Review									
7/1/14-6/30/15*										
7/1/15-6/30/16										
Antidepressant										
7/1/09-6/30/10	5,462	26%	15,688	74%	\$786,111	60%	\$519,290	40%	2,559	
7/1/10-6/30/11	5,335	22%	19,287	78%	\$754,409	49%	\$800,750	51%	2,846	
7/1/11-6/30/12	4,310	16%	22,277	84%	\$736,653	49%	\$774,715	51%	2,856	
7/1/12-6/30/13	2,561	9%	24,647	91%	\$631,605	42%	\$881,158	58%	2,904	
7/1/13-6/30/14*	239	1%	22,163	99%	\$67,074	9%	\$679,477	91%	3,241	
7/1/14-6/30/15*	548	2%	22,174	98%	\$128,668	12%	\$983,688	88%	3,403	
7/1/15-6/30/16	1,717	7%	24,234	93%	\$451,713	31%	\$984,953	69%	3,624	
Anti-anxiety										
7/1/09-6/30/10	76	<1%	18,057	100%	\$21,672	11%	\$171,815	89%	2,931	
7/1/10-6/30/11	49	<1%	19,805	100%	\$17,288	8%	\$191,471	92%	3,032	
7/1/11-6/30/12	48	<1%	21,810	100%	\$18,985	8%	\$207,492	92%	3,128	
7/1/12-6/30/13	51	<1%	18,104	100%	\$22,898	12%	\$173,596	88%	2,838	
7/1/13-6/30/14*	208	2%	12,765	98%	\$120,112	52%	\$108,888	48%	2,482	
7/1/14-6/30/15*	419	3%	13,056	97%	\$153,167	51%	\$148,628	49%	2,529	
7/1/15-6/30/16	335	2%	15,821	98%	\$133,689	42%	\$183,472	58%	2,704	

*Change from last year's reported data is due to health plan's correction of data

United HealthCare QUEST Integration Psychotropic Cost

	Total Number of Claims				Total Expenditure				Total No. Unique Utilizers	
	Brand		Generic		Brand		Generic			
	#	%	#	%	\$	%	\$	%		
Antipsychotic										
	7/1/09-6/30/10	7,268	71%	3,010	29%	\$5,724,344	92%	\$500,395	8%	2,045
	7/1/10-6/30/11	6,953	72%	2,743	28%	\$7,049,618	95%	\$395,039	5%	1,634
	7/1/11-6/30/12	5,760	58%	4,046	42%	\$6,084,993	85%	\$1,032,928	15%	1,493
	7/1/12-6/30/13	3,052	35%	5,691	65%	\$4,532,005	83%	\$902,203	17%	1,593
	7/1/13-6/30/14	2,132	34%	4,212	66%	\$3,219,152	92%	\$290,152	8%	1,500
	7/1/14-6/30/15	1,663	30%	3,798	70%	\$2,831,569	89%	\$343,881	11%	1,183
	7/1/15-6/30/16	899	17%	4,451	83%	\$1,976,129	63%	\$1,140,193	37%	1,208
Antidepressant										
	7/1/09-6/30/10	3,001	28%	7,765	72%	\$736,113	64%	\$417,611	36%	2,697
	7/1/10-6/30/11	1,931	20%	7,954	80%	\$539,340	56%	\$426,176	44%	2,093
	7/1/11-6/30/12	1,146	11%	9,024	89%	\$357,022	56%	\$285,514	44%	1,979
	7/1/12-6/30/13	719	8%	8,865	92%	\$340,744	56%	\$272,948	44%	2,301
	7/1/13-6/30/14	425	5%	8,550	95%	\$217,360	46%	\$258,976	54%	2,519
	7/1/14-6/30/15	147	2%	9,031	98%	\$81,075	21%	\$297,782	79%	2,532
	7/1/15-6/30/16	119	1%	9,258	99%	\$71,632	25%	\$219,943	75%	2,593
Anti-anxiety										
	7/1/09-6/30/10	183	<1%	2,062	99%	\$10,627	5%	\$189,657	95%	2,640
	7/1/10-6/30/11	107	<1%	12,415	99%	\$11,423	5%	\$223,875	95%	2,880
	7/1/11-6/30/12	70	<1%	12,729	99%	\$9,734	5%	\$196,624	95%	2,813
	7/1/12-6/30/13	16	<1%	9,578	100%	\$6,208	4%	\$144,976	96%	2,779
	7/1/13-6/30/14	8	<1%	6,748	100%	\$4,166	6%	\$61,766	94%	1,917
	7/1/14-6/30/15	1	<1%	7,123	100%	\$724	1%	\$49,736	99%	1,949
	7/1/15-6/30/16	1	<1%	6,953	100%	\$78	<1%	\$50,725	100%	2,026

Community Care Services Psychotropic Cost

	Total Number of Claims				Total Expenditure				Total No. Unique Utilizers	
	Brand		Generic		Brand		Generic			
	#	%	#	%	\$	%	\$	%		
Antipsychotic										
	7/1/14-6/30/15*	8,485	33%	17,085	67%	\$9,467,667	71%	\$3,950,018	29%	2,365
	7/1/15-6/30/16	3,053	13%	19,712	87%	\$4,038,550	43%	\$5,441,590	57%	2,286
Antidepressant										
	7/1/14-6/30/15*	622	3%	19,924	97%	\$159,353	15%	\$916,810	85%	2,167
	7/1/15-6/30/16	307	2%	18,224	98%	\$81,700	12%	\$576,783	88%	2,012
Anti-anxiety										
	7/1/14-6/30/15*	16	<1%	6,734	100%	\$1,347	2%	\$81,480	98%	1,044
	7/1/15-6/30/16	12	<1%	6,339	100%	\$721	1%	\$58,200	99%	981

*Change from last year's reported data is due to health plan's correction of data.

Discussion

This report uses “QUEST Integration²” to reflect the Medicaid managed care plans for SFY 2016.

In 2010, section 346-59.9 was amended to require, among other provisions, that access to brand medication be available after two generic failures are documented for antidepressant and anti-anxiety medications. The health plans implemented these amendments during different quarters in SFY 2011.³ Starting in SFY 2012, all the plans became compliant with the amendments. Data for SFY 2010 are provided for comparison.

Two of the five Medicaid managed care plans had data updates. As of the time of this report, data and final analysis are pending verification from one of the plans for the anti-psychotropic medication. For the totals and subtotals that are available, the following are noted:

- 96% of the antidepressant prescriptions are filled as a generic and account for 67% of the antidepressant expenditures. Utilization percentages are stable.
- 99% of the anti-anxiety prescriptions are filled as a generic and account for 72% of the anti-anxiety expenditures. Updated data trends a decrease in generic prescriptions and expenditures for anti-anxiety medications.
- 84% of the anti-psychotropic prescriptions are filled as a generic and account for 49% of the anti-psychotropic expenditures. Initial analysis finds the anti-psychotropic medication brands shifting to generics in number of claims and costs. More anti-psychotropic generics are on the market. Increased claims and costs for one health plan are due to new long acting injectable anti-psychotropic medication.

² On January 1, 2015, QUEST Integration (QI) combined and replaced the State's Medicaid managed care programs, QUEST and QUEST Expanded Access (QExA).

³ The various plans initiated different approaches and combinations during SFY 2011, such as Preferred Drug Lists/Formulary Coverage, Prospective DUR edits, Point-Of-Sale messaging, Step Therapy, Prior Authorization, Provider Education, and Call Center intervention.